Previous Close | 0.605 |
1-Year Change | -82.86% |
6-Months Change | -59.93% |
3-Months Change | -74.15% |
Moving Avg (50d) | 1.4809 |
Moving Avg (200d) | 1.9626 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 72.9M |
Beta (3-Years) | 1.66 |
Revenue Growth (ttm) | 243.09% |
Net Profit Margin (ttm) | -482.47% |
Return On Assets (ttm) | -74.95% |
EPS (ttm) | -1.77 |
PE Ratio (ttm) | -0.34 |
Dividend Yield | % |
Asset Description: | Mersana Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-12-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.617 | 0.635 | 0.647 | 0.666 | 0.696 | 0.726 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.